JP2022515239A5 - - Google Patents
Info
- Publication number
- JP2022515239A5 JP2022515239A5 JP2021536323A JP2021536323A JP2022515239A5 JP 2022515239 A5 JP2022515239 A5 JP 2022515239A5 JP 2021536323 A JP2021536323 A JP 2021536323A JP 2021536323 A JP2021536323 A JP 2021536323A JP 2022515239 A5 JP2022515239 A5 JP 2022515239A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lymphoma
- hydroxymethyl
- tris
- cell lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131002A JP7749080B2 (ja) | 2018-12-21 | 2024-08-07 | 有機化合物の結晶および塩形態およびその医薬組成物 |
| JP2025156833A JP2026001058A (ja) | 2018-12-21 | 2025-09-22 | 有機化合物の結晶および塩形態およびその医薬組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784083P | 2018-12-21 | 2018-12-21 | |
| US62/784,083 | 2018-12-21 | ||
| US201962791571P | 2019-01-11 | 2019-01-11 | |
| US62/791,571 | 2019-01-11 | ||
| US201962882712P | 2019-08-05 | 2019-08-05 | |
| US62/882,712 | 2019-08-05 | ||
| PCT/US2019/067897 WO2020132471A1 (en) | 2018-12-21 | 2019-12-20 | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131002A Division JP7749080B2 (ja) | 2018-12-21 | 2024-08-07 | 有機化合物の結晶および塩形態およびその医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515239A JP2022515239A (ja) | 2022-02-17 |
| JP2022515239A5 true JP2022515239A5 (enExample) | 2022-12-26 |
Family
ID=69185721
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536323A Pending JP2022515239A (ja) | 2018-12-21 | 2019-12-20 | 有機化合物の結晶および塩形態およびその医薬組成物 |
| JP2024131002A Active JP7749080B2 (ja) | 2018-12-21 | 2024-08-07 | 有機化合物の結晶および塩形態およびその医薬組成物 |
| JP2025156833A Pending JP2026001058A (ja) | 2018-12-21 | 2025-09-22 | 有機化合物の結晶および塩形態およびその医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131002A Active JP7749080B2 (ja) | 2018-12-21 | 2024-08-07 | 有機化合物の結晶および塩形態およびその医薬組成物 |
| JP2025156833A Pending JP2026001058A (ja) | 2018-12-21 | 2025-09-22 | 有機化合物の結晶および塩形態およびその医薬組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12297179B2 (enExample) |
| EP (1) | EP3898597A1 (enExample) |
| JP (3) | JP2022515239A (enExample) |
| KR (1) | KR20220035022A (enExample) |
| CN (1) | CN113508108B (enExample) |
| AU (1) | AU2019403396B2 (enExample) |
| BR (1) | BR112021012305A2 (enExample) |
| CA (1) | CA3124401A1 (enExample) |
| CL (1) | CL2021001640A1 (enExample) |
| CO (1) | CO2021009309A2 (enExample) |
| CR (1) | CR20210394A (enExample) |
| GE (2) | GEAP202415700A (enExample) |
| IL (1) | IL284218B1 (enExample) |
| JO (1) | JOP20210147A1 (enExample) |
| MA (1) | MA54541A (enExample) |
| MX (1) | MX2021007536A (enExample) |
| NI (1) | NI202100055A (enExample) |
| PE (2) | PE20212197A1 (enExample) |
| PH (1) | PH12021551495A1 (enExample) |
| SG (1) | SG11202106526UA (enExample) |
| TW (1) | TWI875727B (enExample) |
| UA (1) | UA130491C2 (enExample) |
| WO (1) | WO2020132471A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| ES3063941T3 (en) * | 2020-08-27 | 2026-04-21 | Servier Lab | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
| WO2025227007A1 (en) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001024785A2 (en) | 1999-10-01 | 2001-04-12 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| JP2007015952A (ja) | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| US9012464B2 (en) * | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9360932B1 (en) | 2012-08-29 | 2016-06-07 | Intellect Motion Llc. | Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture |
| CN103965133B (zh) * | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| RS57962B1 (sr) | 2013-02-25 | 2019-01-31 | Aurigene Discovery Tech Ltd | Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| JP6961879B2 (ja) | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| TWI818954B (zh) * | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| CA3184024A1 (en) * | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| ES3063941T3 (en) * | 2020-08-27 | 2026-04-21 | Servier Lab | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
-
2019
- 2019-12-20 JO JOP/2021/0147A patent/JOP20210147A1/ar unknown
- 2019-12-20 US US17/416,910 patent/US12297179B2/en active Active
- 2019-12-20 UA UAA202104251A patent/UA130491C2/uk unknown
- 2019-12-20 AU AU2019403396A patent/AU2019403396B2/en active Active
- 2019-12-20 PE PE2021001052A patent/PE20212197A1/es unknown
- 2019-12-20 EP EP19839747.3A patent/EP3898597A1/en active Pending
- 2019-12-20 GE GEAP202415700A patent/GEAP202415700A/en unknown
- 2019-12-20 CN CN201980091991.XA patent/CN113508108B/zh active Active
- 2019-12-20 WO PCT/US2019/067897 patent/WO2020132471A1/en not_active Ceased
- 2019-12-20 TW TW108147117A patent/TWI875727B/zh active
- 2019-12-20 KR KR1020217022945A patent/KR20220035022A/ko not_active Ceased
- 2019-12-20 GE GEAP201915700A patent/GEP20247683B/en unknown
- 2019-12-20 BR BR112021012305-9A patent/BR112021012305A2/pt unknown
- 2019-12-20 PE PE2025003120A patent/PE20260309A1/es unknown
- 2019-12-20 CR CR20210394A patent/CR20210394A/es unknown
- 2019-12-20 JP JP2021536323A patent/JP2022515239A/ja active Pending
- 2019-12-20 MA MA054541A patent/MA54541A/fr unknown
- 2019-12-20 MX MX2021007536A patent/MX2021007536A/es unknown
- 2019-12-20 CA CA3124401A patent/CA3124401A1/en active Pending
- 2019-12-20 SG SG11202106526UA patent/SG11202106526UA/en unknown
-
2020
- 2020-01-09 PH PH1/2021/551495A patent/PH12021551495A1/en unknown
-
2021
- 2021-06-18 CL CL2021001640A patent/CL2021001640A1/es unknown
- 2021-06-20 IL IL284218A patent/IL284218B1/en unknown
- 2021-06-21 NI NI202100055A patent/NI202100055A/es unknown
- 2021-07-15 CO CONC2021/0009309A patent/CO2021009309A2/es unknown
-
2024
- 2024-08-07 JP JP2024131002A patent/JP7749080B2/ja active Active
-
2025
- 2025-05-07 US US19/201,581 patent/US20250270175A1/en active Pending
- 2025-09-22 JP JP2025156833A patent/JP2026001058A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515239A5 (enExample) | ||
| IL283184B2 (en) | Crystal polymorph of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin–4(5h)–one for the treatment of cancer | |
| TWI610918B (zh) | 治療癌症及骨癌疼痛之方法 | |
| EP3604294B1 (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| JP2021512131A5 (enExample) | ||
| RU2017141035A (ru) | Твердые формы соединения, модулирующего киназы | |
| EA020022B1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа | |
| JP2018515490A5 (enExample) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| CN111012785B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| IL299099B1 (en) | Combinations of cancer treatments | |
| HRP20230477T1 (hr) | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze | |
| RU2010121647A (ru) | Полиморфы ингибитора c-met/hgfr | |
| JP2018534289A5 (enExample) | ||
| JP2016513704A5 (enExample) | ||
| JP2022058492A (ja) | Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬製剤 | |
| EP2874615A1 (en) | Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg | |
| RU2004110042A (ru) | Тиено[2,3-d] пиримидины с комбинированной агонистической активностью lh и fsh | |
| CN113597309B (zh) | 抗肿瘤组合物 | |
| JP5858989B2 (ja) | 組合せ | |
| JP2014005265A5 (enExample) | ||
| EP3471730B1 (en) | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof | |
| TWI374880B (en) | A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof | |
| JP7565118B2 (ja) | （ｓ，ｅ）－４－（ジメチルアミノ）－ｎ－（３－（４－（２－ヒドロキシ－１－フェネチルアミノ）－６－フェニルフロ［２，３－ｄ］ピリミジン－５－イル）フェニル）ブタ－２－エナミド遊離塩基の結晶形 | |
| CN102858342B (zh) | 用于便秘的芳基乙烯基氮杂环烷烃化合物 |